Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Change in Receivables: 2016-2024

Historic Change in Receivables for UroGen Pharma (URGN) over the last 7 years, with Dec 2024 value amounting to $4.9 million.

  • UroGen Pharma's Change in Receivables fell 99.00% to $54,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 million, marking a year-over-year decrease of 131.13%. This contributed to the annual value of $4.9 million for FY2024, which is 77.40% up from last year.
  • Per UroGen Pharma's latest filing, its Change in Receivables stood at $4.9 million for FY2024, which was up 77.40% from $2.7 million recorded in FY2023.
  • UroGen Pharma's Change in Receivables' 5-year high stood at $7.0 million during FY2020, with a 5-year trough of $987,000 in FY2022.
  • Its 3-year average for Change in Receivables is $2.9 million, with a median of $2.7 million in 2023.
  • As far as peak fluctuations go, UroGen Pharma's Change in Receivables slumped by 78.87% in 2022, and later soared by 177.51% in 2023.
  • Over the past 5 years, UroGen Pharma's Change in Receivables (Yearly) stood at $7.0 million in 2020, then plummeted by 33.72% to $4.7 million in 2021, then plummeted by 78.87% to $987,000 in 2022, then skyrocketed by 177.51% to $2.7 million in 2023, then spiked by 77.40% to $4.9 million in 2024.